Elamipretide

Elamipretide
Clinical data
Other names	H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2; D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
Identifiers
	IUPAC name (2S)-6-Amino-2-[[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide;
CAS Number	736992-21-5;
PubChem CID	11764719;
UNII	87GWG91S09;
KEGG	D10925;
Chemical and physical data
Formula	C32H49N9O5
Molar mass	639.802 g·mol−1
	InChI InChI=1S/C32H49N9O5/c1-19-15-22(42)16-20(2)23(19)18-27(41-29(44)24(34)11-8-14-38-32(36)37)31(46)39-25(12-6-7-13-33)30(45)40-26(28(35)43)17-21-9-4-3-5-10-21/h3-5,9-10,15-16,24-27,42H,6-8,11-14,17-18,33-34H2,1-2H3,(H2,35,43)(H,39,46)(H,40,45)(H,41,44)(H4,36,37,38)/t24-,25+,26+,27+/m1/s1; Key:SFVLTCAESLKEHH-WKAQUBQDSA-N;

Elamipretide (also known as SS-31, , MTP-131 and Bendavia)[1][2] is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH₂) that appears to reduce the production of toxic reactive oxygen species and stabilize cardiolipin.[3]

Stealth Peptides, a privately held company, was founded in 2006 to develop intellectual property licensed from several universities including elamipretide; it subsequently changed its name to Stealth BioTherapeutics.[4][5]

As of November 2017 Stealth had obtained an orphan designation in the US for use in mitochondrial myopathy and had started a Phase III trial in that indication.[2] As of January 2020, trial expectations were not met.[6]

References

"Recommended INN List 75" (PDF). WHO Drug Information. 30 (1): 111. 2016.
"Elamipretide". AdisInsight. Retrieved 29 November 2017.
Kloner RA, Shi J, Dai W (February 2015). "New therapies for reducing post-myocardial left ventricular remodeling". Annals of Translational Medicine. 3 (2): 20. doi:10.3978/j.issn.2305-5839.2015.01.13. PMC 4322169. PMID 25738140.
Valigra L (April 9, 2012). "Stealth Peptides sees positive results from Bendavia". Boston Business Journal.
Dolgin E (11 February 2016). "New drugs offer hope for mitochondrial disease". STAT.
PhD, Alberto Molano (2020-01-10). "Elamipretide Failed to Meet Promise of Earlier Trial Results for..." Mitochondrial Disease News. Retrieved 2020-02-24.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Recommended INN List 75" (PDF). WHO Drug Information. 30 (1): 111. 2016.

[adis-2] "Elamipretide". AdisInsight. Retrieved 29 November 2017.

[3] Kloner RA, Shi J, Dai W (February 2015). "New therapies for reducing post-myocardial left ventricular remodeling". Annals of Translational Medicine. 3 (2): 20. doi:10.3978/j.issn.2305-5839.2015.01.13. PMC 4322169. PMID 25738140.

[4] Valigra L (April 9, 2012). "Stealth Peptides sees positive results from Bendavia". Boston Business Journal.

[5] Dolgin E (11 February 2016). "New drugs offer hope for mitochondrial disease". STAT.

[6] PhD, Alberto Molano (2020-01-10). "Elamipretide Failed to Meet Promise of Earlier Trial Results for..." Mitochondrial Disease News. Retrieved 2020-02-24.